Antimicrobial Therapy of Complicated Intra-abdominal Infections: What are the Success Determinants?

Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(2):158-162

​ Golub A.V., Dekhnich A.V., Kozlov R.S.
intra-abdominal infections (IAI) peritonitis antimicrobial therapy extended-spectrum beta-lactamases
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(2):158-162

Abstract

Successful outcome of complicated intra-abdominal infections (peritonitis) is determined by two key factors – surgical control of infection site and appropriate and timely antimicrobial therapy. Over the years choice of high antimicrobials for the treatment of communityacquired peritonitis had previously not a problem because of susceptibility of pathogens to most recommended antimicrobial agents. However, a global trend for community-acquired infections, particularly peritonitis, to be caused by resistant pathogens is observed and requires update of standards for empiric antimicrobial therapy of these infections. A high incidence of extended spectrum beta-lactamase production among Enterobacteriaceae makes carbapenems without anti-pseudomonal activity drugs of choice in the treatment of community-acquired complicated IAI.

  • 1. Савельев В.С., Гельфанд Б.Р., Гологорский В.А. и др. Абдоминальный сепсис: современная концепция и вопросы классификации. Анналы хирургии 1999; 6:14–8.
  • 2. Гостищев В.К., Сажин В.П., Авдовенко А.Л. Перитонит. М: ГэотарМед, 2002. 240 с.
  • 3. Mazuski J.E., Solomkin J.S. Intra-abdominal infections. Surg Clin N Am 2009; 89:421-37.
  • 4. Carlet J., Bouhaja B., Blériot J., Dazza F. Infections péritonéales postopératoires. In: L’infection en réanimation. Régnier B., Brun-Buisson C., éds. Masson, Paris, 1988; 126-138.
  • 5. Зузова А.П., Стецюк О.У., Середкина М.А., и др. Этиология осложненных интраабдоминальных инфекций. Clinical Microbiology and Antimicrobial Chemotherapy.2001; 3(Приложение 1):16.
  • 6. Walker A.P., Krepel C.J., Gohr C.M., et al. Microflora of abdominal sepsis: locus of infection. J Clin Microbiol 1994; 32:557-8.
  • 7. Solomkin J.S., Mazuski J.E., Baron E.J., et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37:997- 1005.
  • 8. Chow J.W., Satishchandran V., Snyder T.A., et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patient with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trend (SMART). Surg Infect 2005; 6:439-48.
  • 9. Paterson D.L., Rossi F., Baquero F., et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patient with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trend (SMART). J Antimicrob Chemother 2005; 55:965-73.
  • 10. Guembe M., Cercenado E., Alcala L., et al. Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003-2007. Rev Esp Quimioter 2008; 21:166-73.
  • 11. Научный отчет о результатах многоцентрового исследования этиологии и антибиотикорезистентности энтеробактерий – возбудителей осложненных интраабдоминальных инфекций в России. Научноисследовательский институт антимикробной химиотерапии. Смоленск, 2010.
  • 12. Solomkin J.S., Yellin A.E., Rotstein O.D., et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. An Surg 2003; 237:235- 45.
  • 13. Козлов Р.С. Селекция резистентных микроорганизмов при использовании антимикробных препаратов: концепция «параллельного ущерба». Clinical Microbiology and Antimicrobial Chemotherapy.2010; 12:284-94.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared